A loss of pRb function occurs in a significant percentage (17 to 26 percent) of breast tumors [14], [15], [16], and together these results suggest that ER+, pRb negative (pRb-) tumors would respond poorly to treatment with antiestrogens. This evidence concerns the gene ESR1 and breast neoplasm.